Idec, GSK, Corixa Discussing Licensing Of Radioimmunotherapy Patents
Executive Summary
Idec is considering licensing patents from Corixa that may cover its radioimmunotherapy Zevalin.
You may also be interested in...
Corixa Bexxar patents ruled invalid
San Diego federal court grants Idec motion for summary judgment Oct. 10, declaring four Bexxar (tositumomab) patents (Nos. 5,595,721; 6,015,542; 6,090,365; 6,287,537) invalid based on inequitable conduct of the inventors in not disclosing highly material prior art before the Patent & Trademark Office. "The manner in which [the work] was brought before the PTO cannot be described as anything short of misleading and inaccurate," the ruling states. Corixa and Bexxar marketing partner GSK originally sought to enjoin Idec from infringing the '721, '542, and '365 patents (1"The Pink Sheet" Sept. 24, 2001, p. 29). Corixa plans to appeal the ruling...
Corixa Bexxar patents ruled invalid
San Diego federal court grants Idec motion for summary judgment Oct. 10, declaring four Bexxar (tositumomab) patents (Nos. 5,595,721; 6,015,542; 6,090,365; 6,287,537) invalid based on inequitable conduct of the inventors in not disclosing highly material prior art before the Patent & Trademark Office. "The manner in which [the work] was brought before the PTO cannot be described as anything short of misleading and inaccurate," the ruling states. Corixa and Bexxar marketing partner GSK originally sought to enjoin Idec from infringing the '721, '542, and '365 patents (1"The Pink Sheet" Sept. 24, 2001, p. 29). Corixa plans to appeal the ruling...
Idec Zevalin May Need Central Monitoring Of Bio-Images, FDA Cmte. Suggests
Idec should establish a centralized monitoring program to assess Zevalin biodistribution images, FDA Oncologic Drugs Advisory Committee Chair Stacy Nerenstone, MD, Helen & Harry Gray Cancer Center, suggested during the Sept. 11 review of the radioimmunotherapy.